Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Head-to-Head, Single-Blind Study to Compare the Efficacy and Safety of Subcutaneous Abatacept Versus Subcutaneous Adalimumab, Both With Background Methotrexate, in Biologic-Naive Subjects With Rheumatoid Arthritis
Brief Summary: The purpose of this study is demonstrate that subcutaneous abatacept is non-inferior (no worse than) to subcutaneous adalimumab in the treatment of subjects with rheumatoid arthritis who are biologic naive


Options:
A: Arm Label: Abatacept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept | Arm Label: Adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Adalimumab | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Adalimumab
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 3
C: Arm Label: 5mg; Type: EXPERIMENTAL; Interventions: Drug: CP 690,550 | Arm Label: 10 mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Sequence 1; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Placebo Sequence 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Biologic TNFi | Intervention Type: DRUG; Name: CP 690,550; Assigned to Arm(s): 5mg | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 10 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Sequence 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Sequence 2 | Intervention Type: BIOLOGICAL; Name: Biologic TNFi; Assigned to Arm(s): adalimumab
D: Arm Label: Phase 1 Etanercept + methotrexate; Type: EXPERIMENTAL; Interventions: Biological: Phase 1: Etanercept, Drug: Phase 1: Methotrexate, Drug: Phase 2: Optional ETN, SSZ, HCQ, MTX | Arm Label: Phase 1 Conventional DMARD (SSZ or HCQ) + MTX; Type: ACTIVE_COMPARATOR; Interventions: Drug: Phase 1: Methotrexate, Drug: Phase 1: Conventiaonal DMARD | Intervention Type: BIOLOGICAL; Name: Phase 1: Etanercept; Assigned to Arm(s): Phase 1 Etanercept + methotrexate | Intervention Type: DRUG; Name: Phase 1: Methotrexate; Assigned to Arm(s): Phase 1 Etanercept + methotrexate | Intervention Type: DRUG; Name: Phase 2: Optional ETN, SSZ, HCQ, MTX; Assigned to Arm(s): Phase 1 Etanercept + methotrexate | Intervention Type: DRUG; Name: Phase 1: Methotrexate; Assigned to Arm(s): Phase 1 Conventional DMARD (SSZ or HCQ) + MTX | Intervention Type: DRUG; Name: Phase 1: Conventiaonal DMARD; Assigned to Arm(s): Phase 1 Conventional DMARD (SSZ or HCQ) + MTX

Answer: A